Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib

Ítems similars

• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  per: Nishino, Mizuki, et al.
  Publicat: (2012)
• Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
  per: Lo, Peter C., et al.
  Publicat: (2015)
• Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression
  per: Nishino, Mizuki, et al.
  Publicat: (2013)
• Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
  per: Li, Yang-Ling, et al.
  Publicat: (2018)
• Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
  per: Digumarthy, Subba R., et al.
  Publicat: (2019)